Go for better access than ever for millions of patients on Medicare Part D
Medicare Part D patients on the largest national plans have access to VYZULTA.
~75%
COVERAGE
in Medicare Part D without a latanoprost failure necessary. No prior authorization (PA) or step edit required.*
Plans include:
For patients who qualify for the Low-Income Subsidy, the copay for VYZULTA is less than $11.†
The insurance plan information in this piece is provided by Bausch + Lomb for informational purposes only. Bausch + Lomb does not guarantee coverage or reimbursement for this product. This information does not guarantee coverage or reimbursement for this product on Humana, AARP, CVS, WellCare, Express Scripts, or other plans. Humana, AARP, CVS, WellCare, and Express Scripts and specific product formulary information are subject to change. Please contact the appropriate Humana, AARP, CVS, WellCare, Express Scripts, or other plan representative for any specific formulary information.
*MMIT Portal, March 2024.
†Centers for Medicare and Medicaid Services, 2023.
Go for optimized savings for millions of patients
Eligible‡ commercially insured patients may pay as little as a
$25COPAY
for a 30-, 60-, or 90-day supply.
No PA or step edit required for patients with Express Scripts.
‡Terms, conditions, and limitations apply. Available exclusively at Walgreens or other participating pharmacies. At non-participating pharmacies, eligible patients may pay as little as a $35 copay. Please see eligibility criteria and terms and conditions at www.BauschAccessProgram.com. Ninety-day supply to be prescribed as 3 bottles of 2.5 mL solution each. Ninety-day supply copay offer only applies if each of the three 2.5-mL bottles is covered by a patient’s commercial insurance.
Patient support made easier
See how VYZULTA performed:
Sign up
Sign up to receive updates and learn more about VYZULTA.
INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
- Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
- Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
- Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
- Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
- There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
- Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
- Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here to see full Prescribing Information.
INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
- Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent